Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan’s 1st Enbrel Biosimilar Makes Its Debut
May 31, 2018
- FDA Action Date for Mogamulizumab Extended for 3 Months: Kyowa Kirin
May 31, 2018
- Kowa to Launch Parmodia after Skipping 3 Listing Rounds
May 30, 2018
- Astellas’s Gilteritinib Gets FDA Priority Status
May 30, 2018
- Perspective on Takeda/Shire Deal - 2: Acquisition Might Mint More Investment Opportunities, Positive or Negative Not Yet Clear
May 30, 2018
- Chugai Files Actemra for Cytokine Release Syndrome
May 30, 2018
- Janssen Japan Chief Calls for Appropriate Rewards for Innovative Drugs
May 29, 2018
- Perspective on Takeda/Shire Deal - 1: Profits Delivered by On-Market Products More Important than Pipeline
May 29, 2018
- Pfizer Submits New Drug Application in Japan for Dacomitinib
May 29, 2018
- MSD Launches Prevymis for Prevention of CMV Infection
May 29, 2018
- JCR to Start PII Study of Hunter Syndrome Treatment in Brazil in June
May 29, 2018
- European Regulator Accepts Mitsubishi Tanabe’s Edaravone Filing for ALS
May 29, 2018
- Takeda Sales Reps Heavily Pitch Inisync, Takecab in February: Anterio Ranking
May 28, 2018
- FDA Extends Action Date for Lenvima’s HCC Indication by 3 Months
May 28, 2018
- AbbVie Seeks Japan Approval for Psoriasis Drug Risankizumab
May 28, 2018
- Opdivo/Yervoy Combo Gains Japan Nod for Melanoma
May 28, 2018
- 3 Generic Major Companies Maintain Double-Digit Growth in FY2017: Jiho Tally
May 28, 2018
- Otsuka/Lundbeck to Launch Add’l PIII for Brexpiprazole in June
May 25, 2018
- Chugai Seeks Still’s Disease Indication for Actemra
May 25, 2018
- Maviret Top Seller Drug in Japan in January-March: IQVIA
May 23, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…